Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids
Court documents have proven that a manufacturer-orchestrated strategy tried to promote gabapentin by distorting evidence in randomized trials. Given this background, we aimed to assess whether implausibly large treatment effects for gabapentin and for a similar gabapentinoid, pregabalin may have been published.
Source: Journal of Clinical Epidemiology - Category: Epidemiology Authors: Karishma Desai, Ian Carroll, Steven Asch, Tina Hernandez-Boussard, John P.A. Ioannidis Tags: Original Article Source Type: research